메뉴 건너뛰기




Volumn 30, Issue 8, 2007, Pages 837-841

Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in age-related macular degeneration in routine clinical practice in Switzerland;Coût-efficacité du traitement par thérapie photodynamique à la verteporfine des membranes néovasculaires dans la dégénérescence maculaire liée à l'àge en pratique clinique en Suisse

Author keywords

Age related macular degeneration; Cost effectiveness; Photodynamic therapy

Indexed keywords


EID: 35648969489     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(07)92619-4     Document Type: Article
Times cited : (7)

References (30)
  • 1
    • 0003520592 scopus 로고
    • Statistics on blindness in the model reporting area 1969-1970
    • Publ no 73-427. Washington: Us Government Printing Office;
    • Kahn HA, Moorehead HB. Statistics on blindness in the model reporting area 1969-1970. United States Department of Healt, Education and Welfare. Publ no 73-427. Washington: Us Government Printing Office; 1973.
    • (1973) United States Department of Healt, Education and Welfare
    • Kahn, H.A.1    Moorehead, H.B.2
  • 2
    • 0020561796 scopus 로고    scopus 로고
    • rd. Senile macular degeneration: a review of epidemiologic features. Am J Epidemiol, 1983;118:132-51.
    • rd. Senile macular degeneration: a review of epidemiologic features. Am J Epidemiol, 1983;118:132-51.
  • 3
    • 0023231173 scopus 로고
    • The dimensions of the problem of eye disease among the elderly
    • Pizzarello LD. The dimensions of the problem of eye disease among the elderly. Ophthalmology, 1987;94:1191-5.
    • (1987) Ophthalmology , vol.94 , pp. 1191-1195
    • Pizzarello, L.D.1
  • 4
    • 26844538065 scopus 로고
    • Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials
    • Macular Photocoagulation study Group
    • Macular Photocoagulation study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol, 1993;107:1374-80.
    • (1993) Arch Ophthalmol , vol.107 , pp. 1374-1380
  • 6
    • 0037230255 scopus 로고    scopus 로고
    • Quality of life with macular degeneration. Perceptions of patients, clinicians and community members
    • Stein JD, Brown MM, Brown GC, Sharma S, Hollands H. Quality of life with macular degeneration. Perceptions of patients, clinicians and community members. Brit J Ophthalmol, 2003;87:8-12.
    • (2003) Brit J Ophthalmol , vol.87 , pp. 8-12
    • Stein, J.D.1    Brown, M.M.2    Brown, G.C.3    Sharma, S.4    Hollands, H.5
  • 7
    • 0342632445 scopus 로고    scopus 로고
    • Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One year results of 2 randomized clinical trials - TAP
    • Treatment of age-related macular degeneration with photodynamic therapy study group
    • Treatment of age-related macular degeneration with photodynamic therapy study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol, 1999;117:1329-45.
    • (1999) Arch Ophthalmol , vol.117 , pp. 1329-1345
  • 8
    • 0035009086 scopus 로고    scopus 로고
    • Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy
    • Verteporfin in Photodynamic Therapy Study Group
    • Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol, 2001;131:541-60.
    • (2001) Am J Ophthalmol , vol.131 , pp. 541-560
  • 9
    • 16844375997 scopus 로고    scopus 로고
    • Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: Two year results of a randomized clinical trial
    • Visudyne in Minimally Classic CNV (VIM) Study Group
    • Visudyne in Minimally Classic CNV (VIM) Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: two year results of a randomized clinical trial. Arch Ophthalmol, 2005;123:448-5.
    • (2005) Arch Ophthalmol , vol.123 , pp. 448-445
  • 10
    • 33748883015 scopus 로고    scopus 로고
    • Fréquence des récidives après thérapie photodynamique à la Verteporfine dans la dégénérescence maculaire liée à l'âge
    • Donati G. Fréquence des récidives après thérapie photodynamique à la Verteporfine dans la dégénérescence maculaire liée à l'âge. J Fr Ophtalmol, 2006;29:803-7.
    • (2006) J Fr Ophtalmol , vol.29 , pp. 803-807
    • Donati, G.1
  • 11
    • 0035555466 scopus 로고    scopus 로고
    • Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with Verteporfin therapy
    • Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with Verteporfin therapy. Seminars in Ophthalmol, 2001;16:218-22.
    • (2001) Seminars in Ophthalmol , vol.16 , pp. 218-222
    • Greiner, R.A.1
  • 12
    • 26844485888 scopus 로고    scopus 로고
    • The Cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data
    • Brown GC, Brown MM, Campanella J, Beauchamp JR. The Cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data. Am J Ophthalmol, 2005;140:679-87.
    • (2005) Am J Ophthalmol , vol.140 , pp. 679-687
    • Brown, G.C.1    Brown, M.M.2    Campanella, J.3    Beauchamp, J.R.4
  • 13
    • 0026575912 scopus 로고
    • How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
    • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J, 1992;146:473-81.
    • (1992) Can Med Assoc J , vol.146 , pp. 473-481
    • Laupacis, A.1    Feeny, D.2    Detsky, A.S.3    Tugwell, P.X.4
  • 14
    • 85031434075 scopus 로고    scopus 로고
    • Five-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 7
    • Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group
    • Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Five-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 7. Arch Ophthalmol, 2005;123:1283-5.
    • (2005) Arch Ophthalmol , vol.123 , pp. 1283-1285
  • 15
    • 0036822175 scopus 로고    scopus 로고
    • Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: Three year results of an open-label extension of 2 randomised clinical trials - TAP
    • Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group
    • Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: three year results of an open-label extension of 2 randomised clinical trials - TAP report no 5. Arch Ophthalmol, 2002;120:1307-14.
    • (2002) Arch Ophthalmol , vol.120 , pp. 1307-1314
  • 17
    • 0242550060 scopus 로고    scopus 로고
    • Cost effectiveness of photodynamic therapy (PDT) with verteporfin in the UK. abstract no. PES6
    • Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy (PDT) with verteporfin in the UK. abstract no. PES6. Value Health, 2002;5:247.
    • (2002) Value Health , vol.5 , pp. 247
    • Smith, D.H.1    Fenn, P.2    Drummond, M.3
  • 18
    • 0034759058 scopus 로고    scopus 로고
    • The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration
    • Sharma S, Brown GC, Brown MB, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology, 2001;108:2051-9.
    • (2001) Ophthalmology , vol.108 , pp. 2051-2059
    • Sharma, S.1    Brown, G.C.2    Brown, M.B.3    Hollands, H.4    Shah, G.K.5
  • 20
    • 0242466582 scopus 로고    scopus 로고
    • Economic evaluation of photodynamic therapy with verteporfin for small subfoveal CNV lesions: The case of Australia [abstract no. PES6]
    • Lees M, Davey P, Price N, Aldridge G, Mudge M, Stokes J. Economic evaluation of photodynamic therapy with verteporfin for small subfoveal CNV lesions: the case of Australia [abstract no. PES6]. Value Health, 2003;110:239.
    • (2003) Value Health , vol.110 , pp. 239
    • Lees, M.1    Davey, P.2    Price, N.3    Aldridge, G.4    Mudge, M.5    Stokes, J.6
  • 21
    • 4344583798 scopus 로고    scopus 로고
    • Cost effectiveness of photodynamic therapy with verteporfin for age reated macular degeneration: The UK case
    • Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age reated macular degeneration: the UK case. Br J Ophthalmol, 2004;88:1107-1112.
    • (2004) Br J Ophthalmol , vol.88 , pp. 1107-1112
    • Smith, D.H.1    Fenn, P.2    Drummond, M.3
  • 22
    • 0035009086 scopus 로고    scopus 로고
    • Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy
    • Verteporfin in Photodynamic Therapy Study Group
    • Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol, 2001;131:541-60.
    • (2001) Am J Ophthalmol , vol.131 , pp. 541-560
  • 24
    • 0031546091 scopus 로고    scopus 로고
    • Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms. AJNR Am J Neurorad, 1997;18:1453-62.
    • Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms. AJNR Am J Neurorad, 1997;18:1453-62.
  • 25
    • 4444250849 scopus 로고    scopus 로고
    • Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation - 'beyond the TAP study. Eye, 2004;18:809-13.
    • Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation - 'beyond the TAP study. Eye, 2004;18:809-13.
  • 26
    • 11244296210 scopus 로고    scopus 로고
    • Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration
    • Frennesson CI, Nilsson SE. Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration. Acta Ophthalmol Scand, 2004;82:645-50.
    • (2004) Acta Ophthalmol Scand , vol.82 , pp. 645-650
    • Frennesson, C.I.1    Nilsson, S.E.2
  • 27
    • 25444443406 scopus 로고    scopus 로고
    • Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration
    • Shyong MP, Lee FL, Chen SJ, Tung TH, Tsai Dc, Hsu WM. Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. J Chin Med Assoc, 2005;68:419-24.
    • (2005) J Chin Med Assoc , vol.68 , pp. 419-424
    • Shyong, M.P.1    Lee, F.L.2    Chen, S.J.3    Tung, T.H.4    Tsai, D.5    Hsu, W.M.6
  • 28
    • 26844485888 scopus 로고    scopus 로고
    • The costutility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data
    • Brown GC, Brown MM, Campanella J, Beauchamp GR. The costutility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data. Am J Ophthalmol, 2005;140:679-87.
    • (2005) Am J Ophthalmol , vol.140 , pp. 679-687
    • Brown, G.C.1    Brown, M.M.2    Campanella, J.3    Beauchamp, G.R.4
  • 29
    • 33749445317 scopus 로고    scopus 로고
    • Ranibizumab for Neovascular Age-Related Macular Degeneration
    • for the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) Study Group
    • Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY for the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) Study Group. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med, 2006;355:1419-31.
    • (2006) N Engl J Med , vol.355 , pp. 1419-1431
    • Rosenfeld, P.J.1    Brown, D.M.2    Heier, J.S.3    Boyer, D.S.4    Kaiser, P.K.5    Chung, C.Y.6    Kim, R.Y.7
  • 30
    • 33749451356 scopus 로고    scopus 로고
    • Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
    • for the treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Study Group
    • Brown DM, Kaiser PK, Michels M, Soubrane GS, Heier JS, Kim RY, Sy JP, Schneider S for the treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Study Group. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. N Engl J Med, 2006;355:1432-44.
    • (2006) N Engl J Med , vol.355 , pp. 1432-1444
    • Brown, D.M.1    Kaiser, P.K.2    Michels, M.3    Soubrane, G.S.4    Heier, J.S.5    Kim, R.Y.6    Sy, J.P.7    Schneider, S.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.